Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma

International Journal of Gynecological Pathology

Volumn 28, Issue 2, 2009, Pages 179-186

  Phillips, V ^a   Kelly, P ^a   McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Immunohistochemistry; Ovary; p16; Serous carcinoma

Indexed keywords

PROTEIN P16; WT1 PROTEIN;

ARTICLE; CARCINOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MUCINOUS CARCINOMA; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROUS CARCINOMA; UNDIFFERENTIATED CARCINOMA;

CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 68949212282     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318182c2d2     Document Type: Article

References (43)

1. McCluggage WG. My thoughts on and approach to the typing of ovarian carcinomas. J Clin Pathol 2008;61:152-163
2. Brugghe J, Baak JP, Wiltshaw E, et al. Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment. Int J Gynecol Cancer 1995;5:262-268
3. Bertelsen K, Holund B, Andersen E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer 1993;3:72-79 (Pubitemid 23209540)
4. Baak JP, Langley FA, Talerman A, et al. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol 1986;8:354-357 (Pubitemid 17230734)
5. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med 1987;111:819-829
6. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS 1991;99:353-358
7. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol 1996;54:54-58 (Pubitemid 24239408)
8. Han G, Gilks CB, Leung S, et al. Interobserver variation in the diagnosis of ovarian clear cell carcinoma and mixed ovarian epithelial carcinomas with a clear cell component. Lab Invest 2007;200A.
9. O'Neill CJ, McBride HA, Connolly LE, et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007;50:773-779
10. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-44 (Pubitemid 38018236)
11. Vang R, Gown AM, Farinola M, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol 2007;31:653-663 (Pubitemid 46684203)
12. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high grade serous carcinoma. Int J Gynecol Pathol 2007;26:328-333 (Pubitemid 46986071)
13. Armes JE, Lourie R, de Silva M, et al. Abnormalities of the Rb1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16 (INK4A) protein. Int J Gynecol Pathol 2005;24:363-368 (Pubitemid 41368290)
14. Shih IM, Kurman RJ. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518
15. Russell HE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004;203:617-619
16. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-1228 (Pubitemid 34411626)
17. Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int J Gynecol Pathol 2003;22:37-41. (Pubitemid 36014274)
18. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-224 (Pubitemid 40170640)
19. Ho C-L, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Can Res 2004;64:6915-6918 (Pubitemid 39330999)
20. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, et al. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest 1999;79:1137-1143 (Pubitemid 29444545)
21. Keating JT, Cviko A, Reithdorf S, et al. Ki-67, cyclin E and p16 are complementary surrogate biomarkers for human papillomavirus related cervical neoplasia. Am J Surg Pathol 2001;25:894-901. (Pubitemid 32594981)
22. Milde-Langosch K, Reithdorf S, Kraws-Poppinghaus A. Expression of cyclin-dependent kinase inhibitors p16, p21 and p27 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 2001;439:55-61.
23. Kalof AN, Evans MF, Simmons-Arnold L, et al. p16 INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol 2005;29:674-679 (Pubitemid 40577879)
24. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006;13:8-15.
25. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-1748 (Pubitemid 28550662)
26. Cameron RI, Maxwell P, Jenkins D, et al. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tuboendometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002;41:313-321 (Pubitemid 35279028)
27. McCluggage WG, Jenkins D. Immunohistochemical staining with p16 may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003;22:231-235 (Pubitemid 36750403)
28. Wentzensen N, du Bois A, Kommoss S, et al. No metastatic cervical adenocarcinomas in a series of p16INK4A positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study Group. Int J Gynecol Pathol 2008;27:18-23.
29. McCluggage WG, Lyness RW, Atkinson RJ, et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002;55:27-31. (Pubitemid 34081677)
30. Miller K, Price JH, Dobbs SP, et al. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J Clin Pathol. In press.
31. Cameron RI, Ashe P, O'Rourke D, et al. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol 2003;22:272-276 (Pubitemid 36750410)
32. Comin CE, Saieva C, Messerini L. H-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007;31:1139-1148 (Pubitemid 47207115)
33. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1β in ovarian and endometrial clear cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 2007;38:1074-1080 (Pubitemid 46899152)
34. Kato N, Sabou S, Motoyama T. Expression of hepatocyte nuclear factor-1 beta (HNF-1 beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006;19:83-89 (Pubitemid 43250982)
35. Cuff J, Esheba GE, Soslow RA, et al. HNF-1 beta expression in ovarian clear cell carcinoma [abstract]. Mod Pathol 2008;21:201A.
36. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004;44:109-115 (Pubitemid 38296970)
37. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004;23:97-99
38. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-163 (Pubitemid 30212153)
39. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27:161-174
40. McCluggage WG, Oliva E, Connolly LE, et al. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. Int J Gynecol Pathol 2004;23:330-336 (Pubitemid 39299021)
41. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol 2003;27:1434-1441 (Pubitemid 37315195)
42. Ansari-Lari MA, Staebler A, Zaino RJ, et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004;28:160-167 (Pubitemid 38124723)
43. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006;19:1091-1100 (Pubitemid 44106724)